Skip to main content
Premium Trial:

Request an Annual Quote

Exact Sciences to Offer 4M Shares in Public Offering

NEW YORK (GenomeWeb) – Exact Sciences said after the close of the market Monday that it will offer 4 million shares of common stock in a public offering.

The shares are being priced at $25.75 each. The offering, which is expected to close on or around Dec. 19, is pursuant to a previously filed shelf registration with the US Securities and Exchange Commission.

Jefferies and Robert W. Baird are the underwriters on the offering and have been granted an option to purchase up to 600,000 additional shares.

Exact Sciences said that it would use net proceeds to fund expansion of its Cologuard commercialization efforts, product development efforts, and general corporate and working capital purposes.

Cologuard was approved for marketing by the US Food and Drug Administration in August. The non-invasive stool-based test is the first FDA-approved colorectal cancer test for screening DNA from stool samples. And last month, the Centers for Medicare & Medicaid Services said that it would reimburse providers $502 per Cologuard test.

In early Tuesday trading on the Nasdaq, shares of Exact Sciences were down 6 percent at $25.36.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.